Top

Current Diabetes Reports

Published in:

Open Access 01-03-2018 | Microvascular Complications—Nephropathy (M Afkarian and B Roshanravan, Section Editors)

The Landscape of Diabetic Kidney Disease in the United States

Authors: O. Kenrik Duru, Tim Middleton, Mona K. Tewari, Keith Norris

Published in: Current Diabetes Reports | Issue 3/2018

Abstract

Purpose of Review

The purposes of this review are to identify population characteristics of important risk factors for the development and progression of diabetic kidney disease (DKD) in the United States and to discuss barriers and opportunities to improve awareness, management, and outcomes in patients with DKD.

Recent Findings

The major risk factors for the development and progression of DKD include hyperglycemia, hypertension, and albuminuria. DKD disproportionately affects minorities and individuals with low educational and socioeconomic status. Barriers to effective management of DKD include the following: (a) limited patient and healthcare provider awareness of DKD, (b) lack of timely referrals of patients to a nephrologist, (c) low patient healthcare literacy, and (d) insufficient access to healthcare and health insurance.

Summary

Increased patient and physician awareness of DKD has been shown to enhance patient outcomes. Multifactorial and multidisciplinary interventions targeting multiple risk factors and patient/physician education may provide better outcomes in patients with DKD.

Available only for authorised users

• United States Renal Data System. USRDS annual data report: epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2017. 2017 [cited 2017 December 7]. Available from: https://www.usrds.org/adr.aspx. Provides up-to-date data on the prevalence and awareness of CKD and ESKD in the United States.

Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–72. https://doi.org/10.1016/S0140-6736(13)60687-X.PubMedCrossRef

Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2014. 2014 [cited 2016 December 7]. Available from: http://www.cdc.gov/diabetes/pdfs/data/2014-report-estimates-of-diabetes-and-its-burden-in-the-united-states.pdf.

Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA. 2015;314(10):1021–9. https://doi.org/10.1001/jama.2015.10029.PubMedCrossRef

• Zelnick LR, Weiss NS, Kestenbaum BR, Robinson-Cohen C, Heagerty PJ, Tuttle K, et al. Diabetes and CKD in the United States population, 2009–2014. Clin J Am Soc Nephrol. 2017. New prevalence data for DKD.

National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(suppl 2):s1–s180.

Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA consensus conference. Am J Kidney Dis. 2014;64(4):510–33. https://doi.org/10.1053/j.ajkd.2014.08.001.PubMedCrossRef

American Diabetes Association. 10. Microvascular complications and foot care. Diabetes Care. 2017;40(Suppl 1):S88–98. https://doi.org/10.2337/dc17-S013.CrossRef

Rowley WR, Bezold C, Arikan Y, Byrne E, Krohe S. Diabetes 2030: insights from yesterday, today, and future trends. Popul Health Manag. 2017;20(1):6–12. https://doi.org/10.1089/pop.2015.0181.PubMedPubMedCentralCrossRef

10.

Delanaye P, Glassock RJ, Pottel H, Rule AD. An age-calibrated definition of chronic kidney disease: rationale and benefits. Clin Biochem Rev. 2016;37(1):17–26.PubMedPubMedCentral

11.

Winearls CG, Glassock RJ. Classification of chronic kidney disease in the elderly: pitfalls and errors. Nephron Clin Pract. 2011;119(Suppl 1):c2–4. https://doi.org/10.1159/000328013.PubMedCrossRef

12.

Szczech LA, Stewart RC, Su HL, DeLoskey RJ, Astor BC, Fox CH, et al. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease). PLoS One. 2014;9(11):e110535. https://doi.org/10.1371/journal.pone.0110535.PubMedPubMedCentralCrossRef

13.

Berhane AM, Weil EJ, Knowler WC, Nelson RG, Hanson RL. Albuminuria and estimated glomerular filtration rate as predictors of diabetic end-stage renal disease and death. Clin J Am Soc Nephrol. 2011;6(10):2444–51. https://doi.org/10.2215/CJN.00580111.PubMedPubMedCentralCrossRef

14.

Turin TC, Ahmed SB, Tonelli M, Manns B, Ravani P, James M, et al. Kidney function, albuminuria and life expectancy. Can J Kidney Health Dis. 2014;1:33. https://doi.org/10.1186/s40697-014-0033-6.PubMedPubMedCentralCrossRef

15.

MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care. 2004;27(1):195–200. https://doi.org/10.2337/diacare.27.1.195.PubMedCrossRef

16.

Molitch ME, Steffes M, Sun W, Rutledge B, Cleary P, de Boer IH, et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care. 2010;33(7):1536–43. https://doi.org/10.2337/dc09-1098.PubMedPubMedCentralCrossRef

17.

MacIsaac RJ, Ekinci EI, Jerums G. Progressive diabetic nephropathy. How useful is microalbuminuria?: contra. Kidney Int. 2014;86(1):50–7. https://doi.org/10.1038/ki.2014.98.PubMedCrossRef

18.

Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829–41. https://doi.org/10.1056/NEJMoa1008862.CrossRef

19.

Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int. 2004;66(4):1596–605. https://doi.org/10.1111/j.1523-1755.2004.00925.x.PubMedCrossRef

20.

Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659–63. https://doi.org/10.1001/archinte.164.6.659.PubMedCrossRef

21.

Leehey DJ, Kramer HJ, Daoud TM, Chatha MP, Isreb MA. Progression of kidney disease in type 2 diabetes—beyond blood pressure control: an observational study. BMC Nephrol. 2005;6(1):8. https://doi.org/10.1186/1471-2369-6-8.PubMedPubMedCentralCrossRef

22.

Robinson-Cohen C, Littman AJ, Duncan GE, Weiss NS, Sachs MC, Ruzinski J, et al. Physical activity and change in estimated GFR among persons with CKD. J Am Soc Nephrol. 2014;25(2):399–406. https://doi.org/10.1681/ASN.2013040392.PubMedCrossRef

23.

Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225–32. https://doi.org/10.1046/j.1523-1755.2003.00712.x.PubMedCrossRef

24.

Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ. 2010;341(sep30 1):c4986. https://doi.org/10.1136/bmj.c4986.PubMedPubMedCentralCrossRef

25.

van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79(12):1341–52. https://doi.org/10.1038/ki.2010.536.PubMedCrossRef

26.

Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20(8):1813–21. https://doi.org/10.1681/ASN.2008121270.PubMedPubMedCentralCrossRef

27.

Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311(8):806–14. https://doi.org/10.1001/jama.2014.732.PubMedPubMedCentralCrossRef

28.

Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA. 2015;313(19):1973–4. https://doi.org/10.1001/jama.2015.4260.PubMedCrossRef

29.

Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, Group US. Risk factors for renal dysfunction in type 2 diabetes: U.K. prospective diabetes study 74. Diabetes. 2006;55(6):1832–9. https://doi.org/10.2337/db05-1620.PubMedCrossRef

30.

Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med. 2013;368(17):1613–24. https://doi.org/10.1056/NEJMsa1213829.PubMedCrossRef

31.

Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care. 2013;36(8):2271–9. https://doi.org/10.2337/dc12-2258.PubMedPubMedCentralCrossRef

32.

Diabetes Control Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.CrossRef

33.

Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–53. https://doi.org/10.1056/NEJMoa052187.PubMedCrossRef

34.

Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.CrossRef

35.

Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39. https://doi.org/10.1056/NEJMoa0808431.PubMedCrossRef

36.

Advance Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.CrossRef

37.

Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340(jan08 1):b4909. https://doi.org/10.1136/bmj.b4909.PubMedPubMedCentralCrossRef

38.

National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60(5):850–86.CrossRef

39.

Begun A, Icks A, Waldeyer R, Landwehr S, Koch M, Giani G. Identification of a multistate continuous-time nonhomogeneous Markov chain model for patients with decreased renal function. Med Decis Mak. 2013;33(2):298–306. https://doi.org/10.1177/0272989X12466731.CrossRef

40.

Hodge M, McArthur E, Garg AX, Tangri N, Clemens KK. Hypoglycemia incidence in older adults by estimated GFR. Am J Kidney Dis. 2017;70(1):59–68. https://doi.org/10.1053/j.ajkd.2016.11.019.PubMedCrossRef

41.

• de Boer IH, Bangalore S, Benetos A, Davis AM, Michos ED, Muntner P, et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(9):1273–84. https://doi.org/10.2337/dci17-0026. Current recommendations for blood pressure control in diabetes.

42.

• Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017. Current recommendations for blood pressure control in diabetes.

43.

Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004;27(6):1496–504. https://doi.org/10.2337/diacare.27.6.1496.PubMedCrossRef

44.

KDIGO. Clinical practice guidelines for lipid management in chronic kidney disease. Kidney Int Suppl. 2013;3(3):271–9.CrossRef

45.

Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011;79(12):1331–40. https://doi.org/10.1038/ki.2010.550.PubMedCrossRef

46.

Amin AP, Whaley-Connell AT, Li S, Chen SC, McCullough PA, Kosiborod MN, et al. The synergistic relationship between estimated GFR and microalbuminuria in predicting long-term progression to ESRD or death in patients with diabetes: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2013;61(4 Suppl 2):S12–23. https://doi.org/10.1053/j.ajkd.2013.01.005.PubMedPubMedCentralCrossRef

47.

Bakris GL, Molitch M. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care. 2014;37(3):867–75. https://doi.org/10.2337/dc13-1870.PubMedCrossRef

48.

Roscioni SS, Lambers Heerspink HJ, de Zeeuw D. Microalbuminuria: target for renoprotective therapy PRO. Kidney Int. 2014;86(1):40–9. https://doi.org/10.1038/ki.2013.490.PubMedCrossRef

49.

Lopez-Novoa JM, Rodriguez-Pena AB, Ortiz A, Martinez-Salgado C, Lopez Hernandez FJ. Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implications. J Transl Med. 2011;9(1):13. https://doi.org/10.1186/1479-5876-9-13.PubMedPubMedCentralCrossRef

50.

Langsford D, Tang M, Cheikh Hassan HI, Djurdjev O, Sood MM, Levin A. The association between biomarker profiles, etiology of chronic kidney disease, and mortality. Am J Nephrol. 2017;45(3):226–34. https://doi.org/10.1159/000454991.PubMedCrossRef

51.

Sun J, Axelsson J, Machowska A, Heimburger O, Barany P, Lindholm B, et al. Biomarkers of cardiovascular disease and mortality risk in patients with advanced CKD. Clin J Am Soc Nephrol. 2016;11(7):1163–72. https://doi.org/10.2215/CJN.10441015.PubMedPubMedCentralCrossRef

52.

Inker LA, Levey AS, Pandya K, Stoycheff N, Okparavero A, Greene T, et al. Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis. 2014;64(1):74–85. https://doi.org/10.1053/j.ajkd.2014.02.020.PubMedPubMedCentralCrossRef

53.

Nicholas SB, Kalantar-Zadeh K, Norris KC. Racial disparities in kidney disease outcomes. Semin Nephrol. 2013;33(5):409–15. https://doi.org/10.1016/j.semnephrol.2013.07.002.PubMedPubMedCentralCrossRef

54.

Nicholas SB, Kalantar-Zadeh K, Norris KC. Socioeconomic disparities in chronic kidney disease. Adv Chronic Kidney Dis. 2015;22(1):6–15. https://doi.org/10.1053/j.ackd.2014.07.002.PubMedPubMedCentralCrossRef

55.

Kurella Tamura M, Anand S, Li S, Chen SC, Whaley-Connell AT, Stevens LA, et al. Comparison of CKD awareness in a screening population using the Modification of Diet in Renal Disease (MDRD) study and CKD Epidemiology Collaboration (CKD-EPI) equations. Am J Kidney Dis. 2011;57(3 Suppl 2):S17–23. https://doi.org/10.1053/j.ajkd.2010.11.008.PubMedCrossRef

56.

• Ene-Iordache B, Perico N, Bikbov B, Carminati S, Remuzzi A, Perna A, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Health. 2016;4(5):e307–19. https://doi.org/10.1016/S2214-109X(16)00071-1. Provides a global perspective on CKD.PubMedCrossRef

57.

Plantinga LC, Boulware LE, Coresh J, Stevens LA, Miller ER 3rd, Saran R, et al. Patient awareness of chronic kidney disease: trends and predictors. Arch Intern Med. 2008;168(20):2268–75. https://doi.org/10.1001/archinte.168.20.2268.PubMedPubMedCentralCrossRef

58.

Whaley-Connell A, Bomback AS, McFarlane SI, Li S, Roberts T, Chen SC, et al. Diabetic cardiovascular disease predicts chronic kidney disease awareness in the Kidney Early Evaluation Program. Cardiorenal Med. 2011;1(1):45–52. https://doi.org/10.1159/000322862.PubMedPubMedCentralCrossRef

59.

Guessous I, McClellan W, Vupputuri S, Wasse H. Low documentation of chronic kidney disease among high-risk patients in a managed care population: a retrospective cohort study. BMC Nephrol. 2009;10(1):25. https://doi.org/10.1186/1471-2369-10-25.PubMedPubMedCentralCrossRef

60.

Tuot DS, Plantinga LC, Hsu CY, Jordan R, Burrows NR, Hedgeman E, et al. Chronic kidney disease awareness among individuals with clinical markers of kidney dysfunction. Clin J Am Soc Nephrol. 2011;6(8):1838–44. https://doi.org/10.2215/CJN.00730111.PubMedPubMedCentralCrossRef

61.

Bruce MA, Beech BM, Crook ED, Sims M, Wyatt SB, Flessner MF, et al. Association of socioeconomic status and CKD among African Americans: the Jackson Heart Study. Am J Kidney Dis. 2010;55(6):1001–8. https://doi.org/10.1053/j.ajkd.2010.01.016.PubMedPubMedCentralCrossRef

62.

Choi AI, Weekley CC, Chen SC, Li S, Tamura MK, Norris KC, et al. Association of educational attainment with chronic disease and mortality: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011;58(2):228–34. https://doi.org/10.1053/j.ajkd.2011.02.388.PubMedPubMedCentralCrossRef

63.

Berkman ND, Sheridan SL, Donahue KE, Halpern DJ, Crotty K. Low health literacy and health outcomes: an updated systematic review. Ann Intern Med. 2011;155(2):97–107. https://doi.org/10.7326/0003-4819-155-2-201107190-00005.PubMedCrossRef

64.

Hall YN, Rodriguez RA, Boyko EJ, Chertow GM, O'Hare AM. Characteristics of uninsured Americans with chronic kidney disease. J Gen Intern Med. 2009;24(8):917–22. https://doi.org/10.1007/s11606-009-1028-3.PubMedPubMedCentralCrossRef

65.

Agrawal V, Jaar BG, Frisby XY, Chen SC, Qiu Y, Li S, et al. Access to health care among adults evaluated for CKD: findings from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2012;59(3 Suppl 2):S5–15. https://doi.org/10.1053/j.ajkd.2011.10.043.PubMedPubMedCentralCrossRef

66.

Hughes-Carter DL, Hoebeke RE. Screening for diabetic kidney disease in primary care for the underinsured: a quality improvement initiative. Appl Nurs Res. 2016;30:148–53. https://doi.org/10.1016/j.apnr.2015.11.008.PubMedCrossRef

67.

Boulware LE, Troll MU, Jaar BG, Myers DI, Powe NR. Identification and referral of patients with progressive CKD: a national study. Am J Kidney Dis. 2006;48(2):192–204. https://doi.org/10.1053/j.ajkd.2006.04.073.PubMedCrossRef

68.

Lea JP, McClellan WM, Melcher C, Gladstone E, Hostetter T. CKD risk factors reported by primary care physicians: do guidelines make a difference? Am J Kidney Dis. 2006;47(1):72–7. https://doi.org/10.1053/j.ajkd.2005.09.027.PubMedCrossRef

69.

Stuckey HL, Vallis M, Kovacs Burns K, Mullan-Jensen CB, Reading JM, Kalra S, et al. “I do my best to listen to patients”: qualitative insights into DAWN2 (Diabetes psychosocial care from the perspective of health care professionals in the second Diabetes Attitudes, Wishes and Needs Study). Clin Ther. 2015;37(9):1986–98 e12. https://doi.org/10.1016/j.clinthera.2015.06.010.PubMedCrossRef

70.

Sinsky C, Colligan L, Li L, Prgomet M, Reynolds S, Goeders L, et al. Allocation of physician time in ambulatory practice: a time and motion study in 4 specialties. Ann Intern Med. 2016;165(11):753–60. https://doi.org/10.7326/M16-0961.PubMedCrossRef

71.

Martinez-Ramirez HR, Jalomo-Martinez B, Cortes-Sanabria L, Rojas-Campos E, Barragan G, Alfaro G, et al. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist. Am J Kidney Dis. 2006;47(1):78–87. https://doi.org/10.1053/j.ajkd.2005.09.015.PubMedCrossRef

72.

Jones C, Roderick P, Harris S, Rogerson M. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transplant. 2006;21(8):2133–43. https://doi.org/10.1093/ndt/gfl198.PubMedCrossRef

73.

Winkelmayer WC, Owen WF Jr, Levin R, Avorn J. A propensity analysis of late versus early nephrologist referral and mortality on dialysis. J Am Soc Nephrol. 2003;14(2):486–92. https://doi.org/10.1097/01.ASN.0000046047.66958.C3.PubMedCrossRef

74.

Kohan DE. Training the next generation of nephrologists. Clin J Am Soc Nephrol. 2011;6(11):2564–6. https://doi.org/10.2215/CJN.08940811.PubMedCrossRef

75.

Sharif MU, Elsayed ME, Stack AG. The global nephrology workforce: emerging threats and potential solutions! Clin Kidney J. 2016;9(1):11–22. https://doi.org/10.1093/ckj/sfv111.PubMedCrossRef

76.

KDIGO. 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150.CrossRef

77.

Vassalotti JA, Centor R, Turner BJ, Greer RC, Choi M, Sequist TD, et al. Practical approach to detection and management of chronic kidney disease for the primary care clinician. Am J Med. 2016;129(2):153–62 e7. https://doi.org/10.1016/j.amjmed.2015.08.025.PubMedCrossRef

78.

Gillespie BW, Morgenstern H, Hedgeman E, Tilea A, Scholz N, Shearon T, et al. Nephrology care prior to end-stage renal disease and outcomes among new ESRD patients in the USA. Clin Kidney J. 2015;8(6):772–80. https://doi.org/10.1093/ckj/sfv103.PubMedPubMedCentralCrossRef

79.

Nee R, Yuan CM, Hurst FP, Jindal RM, Agodoa LY, Abbott KC. Impact of poverty and race on pre-end-stage renal disease care among dialysis patients in the United States. Clin Kidney J. 2017;10(1):55–61. https://doi.org/10.1093/ckj/sfw098

80.

Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411–7. https://doi.org/10.2337/dc13-0331.PubMedPubMedCentralCrossRef

81.

Desai N, Madhavankutty Saraswathy V, Hunter K, McFadden C. Prevalence of true therapeutic inertia in blood pressure control in an academic chronic kidney disease clinic. J Clin Hypertens (Greenwich). 2013;15(6):375–9. https://doi.org/10.1111/jch.12095.CrossRef

82.

Bailie GR, Eisele G, Liu L, Roys E, Kiser M, Finkelstein F, et al. Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects. Nephrol Dial Transplant. 2005;20(6):1110–5. https://doi.org/10.1093/ndt/gfh771.PubMedCrossRef

83.

Muntner P, Judd SE, Krousel-Wood M, McClellan WM, Safford MM. Low medication adherence and hypertension control among adults with CKD: data from the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study. Am J Kidney Dis. 2010;56(3):447–57. https://doi.org/10.1053/j.ajkd.2010.02.348.PubMedPubMedCentralCrossRef

84.

Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int. 2015;2015:217047.PubMedPubMedCentral

85.

Narva AS, Bilous RW. Laboratory assessment of diabetic kidney disease. Diabetes Spectr. 2015;28(3):162–6. https://doi.org/10.2337/diaspect.28.3.162.PubMedPubMedCentralCrossRef

86.

Drawz PE, Archdeacon P, McDonald CJ, Powe NR, Smith KA, Norton J, et al. CKD as a model for improving chronic disease care through electronic health records. Clin J Am Soc Nephrol. 2015;10(8):1488–99. https://doi.org/10.2215/CJN.00940115.PubMedPubMedCentralCrossRef

87.

Tuot DS, Diamantidis CJ, Corbett CF, Boulware LE, Fox CH, Harwood DH, et al. The last mile: translational research to improve CKD outcomes. Clin J Am Soc Nephrol. 2014;9(10):1802–5. https://doi.org/10.2215/CJN.04310514.PubMedPubMedCentralCrossRef

88.

Narva AS, Norton JM, Boulware LE. Educating patients about CKD: the path to self-management and patient-centered care. Clin J Am Soc Nephrol. 2016;11(4):694–703. https://doi.org/10.2215/CJN.07680715.PubMedCrossRef

89.

Norton JM, Moxey-Mims MM, Eggers PW, Narva AS, Star RA, Kimmel PL, et al. Social determinants of racial disparities in CKD. J Am Soc Nephrol. 2016;27(9):2576–95. https://doi.org/10.1681/ASN.2016010027.PubMedPubMedCentral

90.

Goldstein K, Briggs M, Oleynik V, Cullen M, Jones J, Newman E, et al. Using digital media to promote kidney disease education. Adv Chronic Kidney Dis. 2013;20(4):364–9. https://doi.org/10.1053/j.ackd.2013.04.001.PubMedPubMedCentralCrossRef

91.

Bear RA, Stockie S. Patient engagement and patient-centred care in the management of advanced chronic kidney disease and chronic kidney failure. Can J Kidney Health Dis. 2014;1:24. https://doi.org/10.1186/s40697-014-0024-7.PubMedPubMedCentralCrossRef

92.

Wright Nunes J, Greene JH, Wallston K, Eden S, Shintani A, Elasy T, et al. Pilot study of a physician-delivered education tool to increase patient knowledge about CKD. Am J Kidney Dis. 2013;62(1):23–32. https://doi.org/10.1053/j.ajkd.2013.01.023.PubMedCrossRef

93.

Wright-Nunes JA, Luther JM, Ikizler TA, Cavanaugh KL. Patient knowledge of blood pressure target is associated with improved blood pressure control in chronic kidney disease. Patient Educ Couns. 2012;88(2):184–8. https://doi.org/10.1016/j.pec.2012.02.015.PubMedPubMedCentralCrossRef

94.

Devins GM, Mendelssohn DC, Barre PE, Taub K, Binik YM. Predialysis psychoeducational intervention extends survival in CKD: a 20-year follow-up. Am J Kidney Dis. 2005;46(6):1088–98. https://doi.org/10.1053/j.ajkd.2005.08.017.PubMedCrossRef

95.

Devins GM, Mendelssohn DC, Barre PE, Binik YM. Predialysis psychoeducational intervention and coping styles influence time to dialysis in chronic kidney disease. Am J Kidney Dis. 2003;42(4):693–703. https://doi.org/10.1016/S0272-6386(03)00835-7.PubMedCrossRef

96.

Cavanaugh K, Wallston KA, Gebretsadik T, Shintani A, Huizinga MM, Davis D, et al. Addressing literacy and numeracy to improve diabetes care: two randomized controlled trials. Diabetes Care. 2009;32(12):2149–55. https://doi.org/10.2337/dc09-0563.PubMedPubMedCentralCrossRef

97.

Galbraith L, Hemmelgarn B, Manns B, Samuel S, Kappel J, Valk N, et al. The association between individual counselling and health behaviour change: the See Kidney Disease (SeeKD) targeted screening programme for chronic kidney disease. Can J Kidney Health Dis. 2016;3:35.PubMedPubMedCentralCrossRef

98.

National Institutes of Health. National Kidney Disease Education Program (NKDEP). [cited 2017 February 2]. Available from: https://www.niddk.nih.gov/health-information/health-communication-programs/nkdep/Pages/default.aspx.

99.

Fadem SZ. State of the art: chronic kidney disease education. Dial Transplant. 2011;40(9):397–400. https://doi.org/10.1002/dat.20606.CrossRef

100.

Pagels AA, Hylander B, Alvarsson M. A multi-dimensional support programme for patients with diabetic kidney disease. J Ren Care. 2015;41(3):187–94. https://doi.org/10.1111/jorc.12114.PubMedCrossRef

101.

National Kidney Foundation. [cited 2017 February 2]. Available from: https://www.kidney.org/professionals/KLS/cmeprograms.

102.

Medical Education Institute. [cited 2017 February 2]. Available from: https://meiresearch.org.

103.

Renal Physicians Association. [cited 2017 February 2]. Available from: http://rpa.mycrowdwisdom.com/diweb/home.

104.

Moyer VA, Force USPST. Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(8):567–70. https://doi.org/10.7326/0003-4819-157-8-201210160-00533.PubMedCrossRef

105.

Qaseem A, Hopkins RH Jr, Sweet DE, Starkey M, Shekelle P, Clinical Guidelines Committee of the American College of Physicians. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013;159(12):835–47. https://doi.org/10.7326/0003-4819-159-12-201312170-00726.PubMed

106.

American Socity of Nephrology. ASN emphasizes need for early detection of kidney disease, a silent killer. 2013 [cited 2017 May 10]. Available from: https://www.asn-online.org/news/2013/ASN_COMM_ACP_Screening_Response_102213_R12.pdf.

107.

Hoerger TJ, Wittenborn JS, Zhuo X, Pavkov ME, Burrows NR, Eggers P, et al. Cost-effectiveness of screening for microalbuminuria among African Americans. J Am Soc Nephrol. 2012;23(12):2035–41. https://doi.org/10.1681/ASN.2012040347.PubMedPubMedCentralCrossRef

108.

Hoerger TJ, Wittenborn JS, Segel JE, Burrows NR, Imai K, Eggers P, et al. A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening. Am J Kidney Dis. 2010;55(3):463–73. https://doi.org/10.1053/j.ajkd.2009.11.017.PubMedCrossRef

109.

Komenda P, Ferguson TW, Macdonald K, Rigatto C, Koolage C, Sood MM, et al. Cost-effectiveness of primary screening for CKD: a systematic review. Am J Kidney Dis. 2014;63(5):789–97. https://doi.org/10.1053/j.ajkd.2013.12.012.PubMedCrossRef

110.

Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003;290(23):3101–14. https://doi.org/10.1001/jama.290.23.3101.PubMedCrossRef

111.

Yarnoff BO, Hoerger TJ, Simpson SK, Leib A, Burrows NR, Shrestha SS, et al. The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease. BMC Nephrol. 2017;18(1):85. https://doi.org/10.1186/s12882-017-0497-6.PubMedPubMedCentralCrossRef

112.

American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2017;40(suppl 1):s1–s129.

113.

Sarafidis PA, Riehle J, Bogojevic Z, Basta E, Chugh A, Bakris GL. A comparative evaluation of various methods for microalbuminuria screening. Am J Nephrol. 2008;28(2):324–9. https://doi.org/10.1159/000111825.PubMedCrossRef

114.

Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, Norris KC, et al. CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis. 2008;51(4 Suppl 2):S13–20. https://doi.org/10.1053/j.ajkd.2007.12.016.PubMedCrossRef

115.

Bello AK, Peters J, Wight J, El Nahas M. The Kidney Evaluation and Awareness Program in Sheffield (KEAPS): a community-based screening for microalbuminuria in a British population. Nephron Clin Pract. 2010;116(2):c95–103. https://doi.org/10.1159/000314658.PubMedCrossRef

116.

Mathew TH, Corso O, Ludlow M, Boyle A, Cass A, Chadban SJ, et al. Screening for chronic kidney disease in Australia: a pilot study in the community and workplace. Kidney Int Suppl. 2010;116:S9–16.CrossRef

117.

Jolly SE, Li S, Chen SC, Narva AS, Jurkovitz CT, Norris KC, et al. Risk factors for chronic kidney disease among American Indians and Alaska Natives—findings from the Kidney Early Evaluation Program. Am J Nephrol. 2009;29(5):440–6. https://doi.org/10.1159/000174857.PubMedCrossRef

118.

Hwang SJ, Tsai JC, Chen HC. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. Nephrology (Carlton). 2010;15(Suppl 2):3–9. https://doi.org/10.1111/j.1440-1797.2010.01304.x.CrossRef

119.

Satko SG, Sedor JR, Iyengar SK, Freedman BI. Familial clustering of chronic kidney disease. Semin Dial. 2007;20(3):229–36. https://doi.org/10.1111/j.1525-139X.2007.00282.x.PubMedCrossRef

120.

Levey AS, Inker LA, Coresh J. GFR estimation: from physiology to public health. Am J Kidney Dis. 2014;63(5):820–34. https://doi.org/10.1053/j.ajkd.2013.12.006.PubMedPubMedCentralCrossRef

121.

Accetta NA, Gladstone EH, DiSogra C, Wright EC, Briggs M, Narva AS. Prevalence of estimated GFR reporting among US clinical laboratories. Am J Kidney Dis. 2008;52(4):778–87. https://doi.org/10.1053/j.ajkd.2008.05.023.PubMedPubMedCentralCrossRef

122.

Schievink B, Kropelin T, Mulder S, Parving HH, Remuzzi G, Dwyer J, et al. Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18(1):64–71. https://doi.org/10.1111/dom.12583.PubMedCrossRef

123.

Taal MW. Predicting renal risk in the general population: do we have the right formula? Clin J Am Soc Nephrol. 2011;6(7):1523–5. https://doi.org/10.2215/CJN.04200511.PubMedCrossRef

124.

Echouffo-Tcheugui JB, Kengne AP. Risk models to predict chronic kidney disease and its progression: a systematic review. PLoS Med. 2012;9(11):e1001344. https://doi.org/10.1371/journal.pmed.1001344.PubMedPubMedCentralCrossRef

125.

Dunkler D, Gao P, Lee SF, Heinze G, Clase CM, Tobe S, et al. Risk prediction for early CKD in type 2 diabetes. Clin J Am Soc Nephrol. 2015;10(8):1371–9. https://doi.org/10.2215/CJN.10321014.PubMedPubMedCentralCrossRef

126.

Halbesma N, Jansen DF, Heymans MW, Stolk RP, de Jong PE, Gansevoort RT, et al. Development and validation of a general population renal risk score. Clin J Am Soc Nephrol. 2011;6(7):1731–8. https://doi.org/10.2215/CJN.08590910.PubMedCrossRef

127.

Perotte A, Ranganath R, Hirsch JS, Blei D, Elhadad N. Risk prediction for chronic kidney disease progression using heterogeneous electronic health record data and time series analysis. J Am Med Inform Assoc. 2015;22(4):872–80. https://doi.org/10.1093/jamia/ocv024.PubMedPubMedCentralCrossRef

128.

Schutte E, Gansevoort RT, Benner J, Lutgers HL, Lambers Heerspink HJ. Will the future lie in multitude? A critical appraisal of biomarker panel studies on prediction of diabetic kidney disease progression. Nephrol Dial Transplant. 2015;30(Suppl 4):iv96–104. https://doi.org/10.1093/ndt/gfv119.PubMedCrossRef

129.

Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305(15):1553–9. https://doi.org/10.1001/jama.2011.451.PubMedCrossRef

130.

Johns TS, Yee J, Smith-Jules T, Campbell RC, Bauer C. Interdisciplinary care clinics in chronic kidney disease. BMC Nephrol. 2015;16(1):161. https://doi.org/10.1186/s12882-015-0158-6.PubMedPubMedCentralCrossRef

131.

Bayliss EA, Bhardwaja B, Ross C, Beck A, Lanese DM. Multidisciplinary team care may slow the rate of decline in renal function. Clin J Am Soc Nephrol. 2011;6(4):704–10. https://doi.org/10.2215/CJN.06610810.PubMedPubMedCentralCrossRef

132.

Chen PM, Lai TS, Chen PY, Lai CF, Yang SY, Wu V, et al. Multidisciplinary care program for advanced chronic kidney disease: reduces renal replacement and medical costs. Am J Med. 2015;128(1):68–76. https://doi.org/10.1016/j.amjmed.2014.07.042.PubMedCrossRef

133.

McKenzie AL, Hallberg SJ, Creighton BC, Volk BM, Link TM, Abner MK, et al. A novel intervention including individualized nutritional recommendations reduces hemoglobin a1c level, medication use, and weight in type 2 diabetes. JMIR Diabetes. 2017;2(1):e5. https://doi.org/10.2196/diabetes.6981.CrossRef

134.

Chen F, Su W, Becker SH, Payne M, Castro Sweet CM, Peters AL, et al. Clinical and economic impact of a digital, remotely-delivered intensive behavioral counseling program on Medicare beneficiaries at risk for diabetes and cardiovascular disease. PLoS One. 2016;11(10):e0163627. https://doi.org/10.1371/journal.pone.0163627.PubMedPubMedCentralCrossRef

135.

•• Molitch ME, Adler AI, Flyvbjerg A, Nelson RG, So WY, Wanner C, et al. Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int. 2015;87(1):20–30. https://doi.org/10.1038/ki.2014.128. Discusses a number of areas in the management of DKD.PubMedCrossRef

136.

Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–93. https://doi.org/10.1056/NEJMoa021778.PubMedCrossRef

137.

•• Oellgaard J, Gaede P, Rossing P, Persson F, Parving HH, Pedersen O. Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. Kidney Int. 2017. Discusses the impact of intensified, multifactorial treatment on renal outcomes in patients with DKD.

138.

Crowley ST, Belcher J, Choudhury D, Griffin C, Pichler R, Robey B, et al. Targeting access to kidney care via telehealth: the VA experience. Adv Chronic Kidney Dis. 2017;24(1):22–30. https://doi.org/10.1053/j.ackd.2016.11.005.PubMedCrossRef

139.

Haley WE, Beckrich AL, Sayre J, McNeil R, Fumo P, Rao VM, et al. Improving care coordination between nephrology and primary care: a quality improvement initiative using the renal physicians association toolkit. Am J Kidney Dis. 2015;65(1):67–79. https://doi.org/10.1053/j.ajkd.2014.06.031.PubMedCrossRef

140.

Jolly SE, Navaneethan SD, Schold JD, Arrigain S, Konig V, Burrucker YK, et al. Development of a chronic kidney disease patient navigator program. BMC Nephrol. 2015;16(1):69. https://doi.org/10.1186/s12882-015-0060-2.PubMedPubMedCentralCrossRef

Title: The Landscape of Diabetic Kidney Disease in the United States
Authors: O. Kenrik Duru
Tim Middleton
Mona K. Tewari
Keith Norris
Publication date: 01-03-2018
Publisher: Springer US
Published in: Current Diabetes Reports / Issue 3/2018
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-018-0980-x

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The Landscape of Diabetic Kidney Disease in the United States

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2018

Common Models Used for Inpatient Diabetes Management

Clinical Management of Women with Monogenic Diabetes During Pregnancy

Preconception Counseling for Adolescents and Young Adults with Diabetes: a Literature Review of the Past 10 Years

Diabetic Kidney Disease: Is There a Role for Glycemic Variability?

Family-Based Interventions Targeting Improvements in Health and Family Outcomes of Children and Adolescents with Type 1 Diabetes: a Systematic Review

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page